Paul Geudens

Stentys SA engages in the design, development, and marketing of self-expanding stents used in treating cardiovascular diseases. It provides solutions for the treatment of acute myocardial infarction and other complex coronary diseases. Its products include Xposition S, Devoir, AmazoniaSir, stemiCath, Yangtzenano and YangtzeNC. The company was founded by Gonzague Issenmann and Jacques Seguin on July 6, 2006 and is headquartered in Neuilly-sur-Seine, France.

Neuravi Ltd. designs and develops medical devices for the treatment of acute stroke. Through its investment in the Neuravi Thromboembolic Initiative the company supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics to improve patient outcomes in stroke. Neuravi The company was founded by Mahmood K. Razav, Eamon Brady, John O'Shaughnessy and David Vale in 2009 and is headquartered in Galway, Ireland.

Caliber Therapeutics, Inc. is a holding company, which engages in the development of products for atherosclerotic diseases. It offers targeted angioplasty drug delivery balloon, a stent-free delivery platform of anti-restenotic drugs, which enables controlled and targeted drug delivery, reduces thrombosis risk, and reduces the need to implant permanent devices. The company was founded on August 3, 2009 and is headquartered in New Hope, PA.

Part of Stryker Corp., Surpass Medical Ltd. is an Israeli company that provides medical devices. The company is based in Tel Aviv, Israel. Surpass Medical was acquired by Stryker Corp. on November 01, 2012 for $134.99 million.